Bristol Myers Squibb Furnishes Q4 and Full-Year 2025 Financial Results
Summary
On February 5, 2026, Bristol Myers Squibb furnished its financial results for the fourth quarter and full-year 2025 via an earnings press release (Ex. 99.1) and a presentation (Ex. 99.2). The company reported disciplined execution and a focus on long-term growth, alongside providing 2026 guidance. • Fourth quarter revenues increased 1% to $12.5 billion. • Full-year revenues were $48.2 billion. • 2026 revenue guidance is ~$46.0 billion to $47.5 billion, with non-GAAP EPS guidance of $6.05 to $6.35. • Quarterly dividend increased to $0.63 per share, marking the 17th consecutive annual increase.
Why It Matters
This update is material as Bristol Myers Squibb provided its 2026 guidance, projecting revenues of ~$46.0 billion to $47.5 billion and non-GAAP EPS of $6.05 to $6.35 (via Ex. 99.1). This forward-looking information, coupled with a 17th consecutive annual dividend increase to $0.63 per share, offers key insights into future performance and shareholder returns.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how BMY traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View BMY Charts on TradingViewAffiliate link
Is this filing part of a pattern?
One disclosure is noise. Get a structured briefing covering 12 months of SEC filings, disclosure signals, and what to watch next.
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000014272
- Filing Date
- Thursday, February 5, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive